MLYS
Mineralys Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$16.64
+4.06%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$16.41
From 52W high−64.84%
Volume897054.00
Market cap$1.47B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$16.41
From 52W high
−64.84%
Volume
897054.00
Market cap
$1.47B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.6x
P/E (TTM)
—
RSI (14)
27.0
MomentumView details →
1D Return
+4.06%
YTD Return
−55.72%
SummaryUpdated Jun 1, 2026
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Radnor, Pennsylvania. The company went public in February 2023 and focuses on developing innovative therapies for hypertension and associated cardiovascular diseases. Mineralys is currently advancing its lead drug candidate, lorundrostat, through multiple Phase III clinical trials targeting patients with uncontrolled and resistant hypertension, representing a significant unmet medical need affecting millions of patients worldwide.
Similar companies
Latest newsMore news →
Mineralys Therapeutics terminated its License Agreement with Tanabe Pharma, and Tanabe assigned the transferred intellectual property to Mineralys under a Termination Agreement.6d agoMineralys Therapeutics, Inc. announced that it will report financial results for the third quarter ended September 30, 2026, after market close on November 4, 2026.7d agoMineralys Therapeutics, Inc. announced publication of Phase 2 Explore-CKD trial results showing that lorundrostat 25 mg once daily added to an SGLT2 inhibitor met the primary endpoint with a statistically significant reduction in systolic blood pressure at four weeks.7d ago